Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study.

Like Comment
The treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high-dose methotrexate (IV HD-MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first-line treatment with HD-MTX between 2011-2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL-10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL-10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow-up of 61 months, 41/59 (69%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression-free survival, ocular-free survival and brain-free survival were 75, 18, 29 and 73 months, respectively. IV HD-MTX based systemic therapy as a first-line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL-10. This article is protected by copyright. All rights reserved.

View the full article @ American journal of hematology

Get PDF with LibKey
Authors: Marion Lam, Valérie Touitou, Sylvain Choquet, Nathalie Cassoux, Hervé Ghesquières, Laurent Kodjikian, Anna Schmitt, Sarra Gattoussi, Émeline Tabouret, Magali Sampo, Marie Blonski, Karine Angioi-Duprez, Roch Houot, Frédéric Mouriaux, Emmanuel Gyan, Marie-Laure Le Lez, Marie-Pierre Moles, Fabien Croisé, Adrien Chauchet, Claire Schwartz, Guido Ahle, Laurent Meyer, Rémy Gressin, Christophe Chiquet, Lucie Oberic, Priscille Ollé, Jean-Pierre Marolleau, Benjamin Jany, Adrian Tempescul, Béatrice Cochener, Gandhi Damaj, Jean-Claude Quintyn, Cécile Chabrot, Eve Rousseau, Paul Franciane, Christelle Schneider, Hélène Massé, Jérôme Tamburini Bonnefoy, Antoine Brézin, Luc-Matthieu Fornecker, Laurent Ballonzoli, Magali Le Garff-Tavernier, Khê Hoang-Xuan, Bahram Bodaghi, Carole Soussain, Caroline Houillier


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following